Researchers prevent heart failure in mice

The hearts of the mice that possess more of the microRNAs 212 and 132 (on the right) are distinctly larger than the hearts of the normal mice (on the left). © Kamal Chowdhury / Max Planck Institute for Biophysical Chemistry

(Medical Xpress)—Cardiac stress, for example a heart attack or high blood pressure, frequently leads to pathological heart growth and subsequently to heart failure. Two tiny RNA molecules play a key role in this detrimental development in mice, as researchers at the Hannover Medical School and the Göttingen Max Planck Institute for Biophysical Chemistry have now discovered. When they inhibited one of those two specific molecules, they were able to protect the rodent against pathological heart growth and failure. With these findings, the scientists hope to be able to develop therapeutic approaches that can protect humans against heart failure.

Respiratory distress, fatigue, and attenuated performance are symptoms that can accompany heart failure. Germany-wide approximately 1.8 million people suffer from this disease. A reason for this can be an enlarged heart, a so-called . It may develop when the heart is subjected to permanent stress, for example, due to persistent or a valvular heart defect. In order to boost the pumping performance, the enlarge – a condition that frequently results in heart failure if not treated.

Two small RNA molecules tip the balance

A research team at the Göttingen Max Planck Institute for and the Hannover Medical School discovered that two small play a key role in the growth of heart muscle cells: the microRNAs miR-212 and miR-132. The scientists had observed that these microRNAs are more prevalent in the of mice suffering from cardiac hypertrophy. To determine the role that the two microRNAs play, the scientists bred genetically modified mice that had an abnormally large number of these molecules in their heart muscle cells. "These rodents developed cardiac hypertrophy and lived for only three to six months, whereas their healthy conspecifics had a normal healthy life-span of several years," explained Dr. Kamal Chowdhury, researcher in the Department of Molecular Cell Biology at the Institute for Biophysical Chemistry. "For comparison, we also selectively switched off these microRNAs in other mice. These animals had a slightly smaller heart than their healthy conspecifics, but did not differ from them in behavior or life-span," continued the biologist. The crucial point is when the scientists subjected the hearts of these mice to stress by narrowing the aorta, the mice did not develop cardiac hypertrophy – in contrast to normal mice.

A microRNA inhibitor protects mice against hypertrophy

The scientists were also able to protect normal mice against the disease. When they gave them a substance that selectively inhibits microRNA-132, no pathological cardiac growth occurred – even when the hearts of these mice were subjected to stress. "Thus, for the first time ever, we have found a molecular approach for treating pathological cardiac growth and heart failure in mice," said the cardiologist Professor Dr. Dr. Thomas Thum, MD, Director of the Institute for Molecular and Translational Therapy Strategies (IMTTS) at the Hannover Medical School. With these findings, the researchers hope that they will be able to develop therapeutic approaches that can also protect humans against . "Such microRNA inhibitors, alone or in combination with conventional treatments, could represent a promising new therapeutic approach," said Thum.

"In mice with an overdosage of the two microRNAs in their heart muscle cells, the cellular 'recycling program' is curbed," explained Dr. Ahmet Ucar, who together with Shashi K. Gupta was responsible for the experiments. In this recycling process, the cell breaks down components that are damaged or no longer required and reuses their constituents – a vital process that, for example, ensures the organism's survival under stress conditions. In mice without the microRNAs -212 and 132, this recycling program is more active than in their normal conspecifics. Conceivably, the reduced cellular recycling could be a cause of the observed cardiac hypertrophy.

More information: Ahmet Ucar, Shashi K. Gupta, Jan Fiedler, Erdem Erikci, Michal Kardasinski, Sandor Batkai, Seema Dangwal, Regalla Kumarswamy, Claudia Bang, Angelika Holzmann, Janet Remke, Massimiliano Caprio, Claudia Jentzsch, Stefan Engelhardt, Sabine Geisendorf, Carolina Glas, Thomas G. Hofmann, Michelle Nessling, Karsten Richter, Mario Schiffer, Lucie Carrier, L. Christian Napp, Johann Bauersachs, Kamal Chowdhury, Thomas Thum: The miRNA-212/132 family regulates both cardiac hypertrophy and autophagy. Nature Communications, 25. September 2012, doi: 10.1038/ncomms2090

Related Stories

Hormone reduces risk of heart failure from chemotherapy

Aug 04, 2011

Recent studies have shown that the heart contains cardiac stem cells that can contribute to regeneration and healing during disease and aging. However, little is known about the molecules and pathways that regulate these ...

Enzyme weakens the heart

Feb 17, 2009

An enzyme makes the mouse heart prone to chronic cardiac insufficiency - if it is suppressed, the heart remains strong despite increased stress. Cardiologists at the Internal Medicine Clinic at Heidelberg University Hospital ...

Novel method used to treat obese mice

Mar 07, 2006

Johns Hopkins scientists, working on genetically engineered obese mice, have used a nerve protection and growth factor to cut the size of the heart muscle.

Recommended for you

Huge discrepancies on heart disease in Europe

8 hours ago

Russians and Ukrainians aged 55 to 59 die from coronary heart disease at a higher rate than Frenchmen who are 20 years older, a study released Wednesday of Europe's cardiovascular health showed.

Common antibiotic linked with heart deaths

18 hours ago

The antibiotic clarithromycin—widely used for treating common bacterial infections—is associated with an increased risk of heart deaths, finds a study published in the BMJ today.

User comments